%0 Journal Article %T Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report %+ Service de néphrologie [Rennes] %+ Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes] %+ CHU Pontchaillou [Rennes] %+ Institut de recherche en santé, environnement et travail (Irset) %A Thibaud, Vincent %A Rivalan, Joseph %A Llamas, Francisco %A Cherel, Mathilde %A Decaux, Olivier %A Vigneau, Cécile %< avec comité de lecture %@ 1769-7255 %J Néphrologie & Thérapeutique %I Elsevier Masson %V 14 %N 7 %P 544-547 %8 2018-12 %D 2018 %R 10.1016/j.nephro.2018.07.404 %M 30301610 %K Immunosuppression %K Multiple myeloma %K Myeloma %K Plasmacytoma %K Post-transplant lymphoproliferative disorder %K Transplantation %Z Life Sciences [q-bio] %Z Life Sciences [q-bio]/Human health and pathologyJournal articles %X Post-transplantation lymphoproliferative disorder (PTLD) is a well-know complication after organ transplantation. We report a case of a patient who developed an extramedullary plasmacytoma-like PTLD around his transplanted kidney treated with standard multiple myeloma chemotherapy. Three years after benefiting of a deceased donor kidney transplant for an end stage kidney disease secondary to nephroangiosclerosis, our patient developed an extra-medullary plasmacytoma confined to the transplant compartment. The transplant function was unaltered, and due to the absence of reduction of the lesion after immunosuppression reduction, a chemotherapy by bortezomib-cyclophosphamide-dexamethasone (VCD) known to be efficient in multiple myeloma was initiated. After 6 cycles, positron emission tomography (PET) scan showed complete metabolic remission confirming the biological exams. This case report suggests that a chemotherapy such as VCD can efficiently treat plasmacytoma-like PTLD allowing graft survival. Therefore, transplant removal may not be mandatory as the best second line treatment after unsuccessfulness reduction of immunosuppression. %G English %L hal-02445398 %U https://univ-rennes.hal.science/hal-02445398 %~ UNIV-RENNES1 %~ UNIV-ANGERS %~ IFR140 %~ HL %~ IRSET %~ IRSET-TREC %~ IRSET-NEED %~ IRSET-TNGC %~ UR1-UFR-SVE %~ UR1-HAL %~ UR1-SDV %~ IRSET-8 %~ TEST-UR-CSS %~ UNIV-RENNES %~ UR1-BIO-SA